EUCTR2007-003528-39-DKActive, not recruitingPhase 1
A Randomized, International, Double-Blinded (With In-HouseBlinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability,Immunogenicity, and Efficacy Study of a Multivalent HumanPapillomavirus (HPV) L1 Virus-Like Particle (VLP) VaccineAdministered to 16- to 26-Year-Old Women - FUTURE 9
Merck & Co. Inc.0 sites14,620 target enrollmentStarted: August 28, 2007Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 14,620
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- Female
Inclusion Criteria
- •1. Subject is female, between the ages of 16 years and 0 days and 26 years and 364 days on the day of randomization.
- •2. Subject has never had Pap testing or has only had normal Pap test results.
- •3. The subject has the following lifetime sexual history at the time of enrollment:
- •a) Subject has had 1 to 4 male and/or female sexual partners; or
- •b) Subject has had 0 male and/or female sexual partners, is 18 years of age or older, and plans to become sexually active within the first 3 months of the study.
- •4. Since the first day of the subject’s last menstrual period through Day 1, the subject has not had sex with males or has had sex with males and used effective contraception with no failures (an example of a failure is a male condom that ruptures during sexual intercourse).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1. Subject has a history of an abnormal cervical biopsy result (showing cervical intraepithelial neoplasia [CIN] or worse).
- •2. Subject has a history of a positive test for HPV.
- •3. Subject has received a marketed HPV vaccine, or has participated in an HPV vaccine clinical trial and has received either active agent or placebo.
- •4. Subject is pregnant (as determined by a serum pregnancy test or urine pregnancy test that is sensitive to 25 mIU/mL ß-hCG).
- •5. Subject has a history of or clinical evidence at the Day 1 pelvic examination of HPV-related external genital lesions (e.g., condyloma acuminata or vulvar intraepithelial neoplasia [VIN]) or external genital cancer, HPV-related vaginal lesions (e.g., condyloma acuminata or vaginal intraepithelial neoplasia [VaIN]) or vaginal cancer.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26-Year-Old Women.Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 18.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2007-003528-39-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA14,620
Active, not recruiting
Phase 1
A Randomized, International, Double-Blinded (With In-House Blinding), ControlledWith GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a SecondGeneration Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) VaccineAdministered to 16- to 26-Year-Old WomePrevention of cervical, vulvar, and vaginal cancers and related precancers, externalgenital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11,16, 18, 31, 45, 52, and 58.MedDRA version: 8.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionEUCTR2006-004933-14-DKMerck & Co., Inc.4,000
Completed
Not Applicable
A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26-Year-Old Wome-B977 Papillomavirus as the cause of diseases classified to other chaptersPapillomavirus as the cause of diseases classified to other chaptersB977PER-064-07MERCK SHARP & DOHME PERU S.R.L.,785
Active, not recruiting
Phase 1
A GARDASIL®-Controlled Study of Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 23 Year-Old Women.vaccination against HPV infection/related diseaseMedDRA version: 19.1Level: LLTClassification code 10071147Term: Human papilloma virus immunizationSystem Organ Class: 100000004865EUCTR2017-000109-19-Outside-EU/EEAMerck & Co., Inc.680
Active, not recruiting
Not Applicable
An International Study of an HPV Vaccine in 16- to 26-Year-Old WomePrevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 17.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2007-003528-39-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.14,620